Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.39 and traded as low as $0.3550. Prima BioMed shares last traded at $0.3551, with a volume of 107,492 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on IMMP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a research note on Friday, July 10th. Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.50.
Read Our Latest Analysis on IMMP
Prima BioMed Stock Performance
Prima BioMed (NASDAQ:IMMP – Get Free Report) last released its earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $3.68 million during the quarter.
Institutional Trading of Prima BioMed
An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC raised its position in Prima BioMed Ltd (NASDAQ:IMMP – Free Report) by 14.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company’s stock.
About Prima BioMed
Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.
Further Reading
- Five stocks we like better than Prima BioMed
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
